I notice the filing content is cut off, but there is sufficient substantive disclosure to work with from what is provided. Let me produce the article based on the available information.

Entrada Therapeutics, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 5, 2026, covering the fiscal quarter ended September 30, 2026.

Key Highlights

  • Shares outstanding: As of October 31, 2026, Entrada Therapeutics had 39,150,334 shares of common stock, $0.0001 par value per share, outstanding.
  • Filer status: The company is classified as an accelerated filer, a smaller reporting company, and an emerging growth company under SEC rules.
  • Going concern disclosure: The filing lists among its forward-looking statements "substantial doubt regarding our ability to continue as a going concern and our need to raise capital in the near term in order to maintain our operations."
  • Exchange listing: Common stock is registered on The Nasdaq Global Market under the trading symbol TRDA, with a par value of $0.0001 per share.
  • Extended transition period: The company has not elected to use the extended transition period for complying with new or revised financial accounting standards under Section 13(a) of the Exchange Act.

Entrada Therapeutics Q3 2026 Quarterly Report: Key Disclosures and Going Concern Language

Entrada Therapeutics, Inc. (NASDAQ:TRDA), a Delaware-incorporated biopharmaceutical company headquartered at One Design Center Place, Suite 17-500, Boston, MA 02210, submitted its Form 10-Q for the quarterly period ended September 30, 2026. The filing was made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, with Commission File Number 001-40969. As of October 31, 2026, the registrant reported 39,150,334 shares of common stock outstanding at a par value of $0.0001 per share.

Among the notable disclosures in the filing's cautionary forward-looking statements section, the company explicitly cited "substantial doubt regarding our ability to continue as a going concern and our need to raise capital in the near term in order to maintain our operations" as a topic addressed by forward-looking statements in the report. The filing attributes these statements to management's current beliefs, expectations, and assumptions, and notes they involve "known and unknown risks, uncertainties and other factors" that could cause actual results to differ materially from those expressed or implied.

The report also covers the company's EEV Platform, described in the filing as a proprietary platform the company seeks to leverage to develop therapeutic candidates. Additional forward-looking topics identified in the filing include the timing of clinical trials and regulatory filings, manufacturing scale-up, potential collaboration arrangements, and the period over which available financial resources are estimated to sustain operations. The company confirmed it is not a shell company and has met all required electronic filing obligations under Rule 405 of Regulation S-T during the preceding 12 months.

What Was Disclosed

Entrada Therapeutics filed a Form 10-Q for the quarter ended September 30, 2026, disclosing 39,150,334 shares outstanding as of October 31, 2026, its filer classifications, and forward-looking statements that include going concern language regarding the need to raise capital in the near term.